logo
World's first sound-powered microscope sees 5x deeper into brain without altering cells

World's first sound-powered microscope sees 5x deeper into brain without altering cells

Yahoo2 days ago
For decades, scientists have pushed the limits of microscopy to capture sharper and deeper views of the brain. Traditional light-based systems can map the cortex in detail but struggle to reach deeper regions like the hippocampus without losing resolution.
The challenge is even greater when imaging molecular activity inside single cells, which is an essential step in understanding brain function and diseases.
MIT scientists and engineers have now built a microscope that overcomes this barrier by combining ultrafast light pulses with sound detection.
The system can image at depths more than five times greater than existing methods without using dyes, chemicals, or genetic modification. Researchers believe it could transform neuroscience research and surgical applications.
Seeing deeper into the brain
The study shows the system can detect NAD(P)H, a molecule linked to cell metabolism and neuronal activity, through dense brain samples. Tests included a 1.1 millimetre thick human stem cell-derived cerebral organoid and a 0.7 millimetre slice of mouse brain tissue.
'That's when we hit the glass on the other side,' said W. David Lee, the postdoctoral researcher who designed the system, explaining that the samples were not large enough to push the technology's true limits.
The device uses a three-photon excitation method, firing ultrashort light bursts at triple the molecule's normal absorption wavelength. These longer wavelengths scatter less and penetrate deeper into tissue.
Most of the absorbed energy creates a rapid, microscopic thermal expansion inside the cell, generating sound waves.
A sensitive ultrasound microphone detects these waves, and software turns them into sharp images. This process is called three-photon photoacoustic imaging.
Merging advanced imaging techniques
The team combined three-photon excitation, photoacoustic detection, and label-free imaging into a platform they call 'Multiphoton-In and Acoustic-Out.' This setup allows precise molecular detection without altering the tissue.
The system can also identify other molecules, such as GCaMP, a calcium indicator used to track neural activity. Additionally, 'third-harmonic generation' imaging maps cellular structures, giving structural and molecular detail in the same scan.
Co-lead author Tatsuya Osaki from The Picower Institute said the aim was to combine advanced techniques into one efficient process.
This capability could help study conditions where NAD(P)H levels change, including Alzheimer's disease, Rett syndrome, and seizures.
Because it works without labels, it could also guide brain surgeries by mapping activity in real time.
The next goal is to test the system in living animals. In this case, both the light source and microphone will need to be on the same side of the tissue instead of opposite sides.
Lee expects the system could image up to 2 millimetres deep in live brains. 'In principle it should work,' he said.
Lee's earlier work through Precision Healing Inc. showed that NAD(P)H imaging can guide wound treatment. Now, the same approach may prove valuable for neurosurgery and brain research.
The project was funded by the National Institutes of Health, the Simon Center for the Social Brain, The Picower Institute, and other sources.
The study is published in the journal Light: Science and Applications.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time12 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time12 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

White House says chips deals could perhaps expand to other companies
White House says chips deals could perhaps expand to other companies

Yahoo

time12 minutes ago

  • Yahoo

White House says chips deals could perhaps expand to other companies

(Refiles to fix capitalization in headline, add period to end of second paragraph) (Reuters) -The White House said on Tuesday that perhaps deals could be expanded to other chip companies after Nvidia and Advanced Micro Devices agreed to give the U.S. government 15% of revenue from sales to China of certain advanced chips. "It stands with these two companies, perhaps it could expand in the future to other companies. I think it's a creative idea and solution," press secretary Karoline Leavitt said during a press briefing.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store